ac investment research

Should I Buy NASDAQ:TTNP Stock? (8% Forecasted Return) | TTNP Titan Pharmaceuticals Stock Forecast



In addition, a speculative-grade company's access to the credit markets during times of stress, such as the financial crisis, is often a function of the capital market's appetite for risk. Accordingly, it would be rare that we would characterize a speculative-grade company as having a generally high standing in the credit markets, and even low-investment-grade companies may not have access to a diversity of funding sources required for this assessment.In determining how prudent a company's risk management is, we look for evidence that management has historically anticipated potential company-specific or market-related setbacks and has taken necessary actions to ensure sufficient liquidity. We estimate TTNP Titan Pharmaceuticals stock forecast parameters by: Momentum with Simple Regression because of management has no or few defined standards and tolerances and little risk management capability (8% Forecasted Return)

NASDAQ:TTNP Stock Forecast (Buy or Sell) as of 24 Jun 2022 for (n+4 weeks)

Stock: TTNP Titan Pharmaceuticals

Time series to forecast n: 24 Jun 2022 for (n+4 weeks)

x axis:Likelihood %
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %

Stock Forecast Criteria and Models for TTNP Titan Pharmaceuticals

  • Residual time to the effective maturity date of at least 15 years if the SACP is 'bbb–' or higher; or at least 10 years if the bank's SACP is 'bb+' or lower. We use the ICR as a reference point if the issuer is an NOHC
  • We assume that 20% of total AUM pertains to monetary funds when the breakdown by type of funds is not available.
  • Under our RACF, we multiply by 1.5 any regulatory charge that has been computed using internal models (including VaR, SVaR, IRC, and CRM) when a bank does not disclose which model or which combination of models it has used. We apply this multiplier in particular when a bank reports the total of the regulatory charge, computed according to internal models, without providing any breakdown by component.
  • For governmental entities, the quantitative factors we assess are different from the factors we assess for business entities; they generally include both economic factors and budgetary and financial performance, as well as additional items for sovereign obligors. The economic side of the analysis typically encompasses demographics, wealth, and growth prospects. The budgetary and financial side generally includes budget reserves, external liquidity, and structural budget performance. For sovereign obligors, additional quantitative factors that may, in our view, be relevant to our analysis include fiscal policy flexibility, monetary policy flexibility, international investment position, and contingent liabilities associated with potential support for the financial sector.
  • Our charges on equity investments (for equity exposures that are not captured elsewhere, such as equities that are classified in banks' trading books) capture the risk of loss at a one-year horizon in an 'A' stress scenario. They correspond to our estimates of potential losses in the stress scenario on the assumption of a "buy and hold" strategy.
  • For entities not subject to a regulatory CVA charge (e.g., some securities firms or banks in non-Basel III jurisdictions) and that exceed the above thresholds, the RAC CVA charge is zero if we believe that exposures to OTC not cleared through a CCP derivatives represent only a very small fraction of derivatives exposures for the firm.
  • We distinguish mortgage servicing rights (MSRs), which are servicing-related intangible assets, from nonservicing intangible assets. This is because MSRs are written contractual obligations that can be sold. Rather than deducting a portion of the MSRs from our equity measures, as some regulators do, we reflect the risk of fluctuating MSR values by applying a RACF capital charge to servicing intangibles.

Assumptions Underlying The Forecast Model for TTNP Titan Pharmaceuticals

For exceptional and strong liquidity assessments, we characterize standing in the credit markets as generally high, and for adequate liquidity, we view standing in the credit markets as satisfactory. We distinguish between these descriptors based on analytical judgment and mainly consider the diversity of funding sources available to an entity.

Frequently Asked QuestionsQ: Is TTNP Titan Pharmaceuticals stock buy or sell?
A: In addition, a speculative-grade company's access to the credit markets during times of stress, such as the financial crisis, is often a function of the capital market's appetite for risk. Accordingly, it would be rare that we would characterize a speculative-grade company as having a generally high standing in the credit markets, and even low-investment-grade companies may not have access to a diversity of funding sources required for this assessment.
Q: Is TTNP Titan Pharmaceuticals stock expected to go up?
A: In determining how prudent a company's risk management is, we look for evidence that management has historically anticipated potential company-specific or market-related setbacks and has taken necessary actions to ensure sufficient liquidity.
Q: What is the forecast for TTNP Titan Pharmaceuticals ?
A: For exceptional and strong liquidity assessments, we characterize standing in the credit markets as generally high, and for adequate liquidity, we view standing in the credit markets as satisfactory. We distinguish between these descriptors based on analytical judgment and mainly consider the diversity of funding sources available to an entity.
Q: What is the consensus rating of TTNP Titan Pharmaceuticals ?
A: The consensus rating for TTNP Titan Pharmaceuticals is 79.
Q: What are the risks of investing TTNP Titan Pharmaceuticals ?
A: We use risk analysis for TTNP Titan Pharmaceuticals because of management has no or few defined standards and tolerances and little risk management capability


TTNP Titan Pharmaceuticals
AC Investment Research

In our experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.

301 Massachusetts Avenue Cambridge, MA 02139 667-253-1000 pr@ademcetinkaya.com